Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: A randomized, placebo-controlled, double-blind trial

Journal of Clinical Pharmacology

Volumn 46, Issue 4, 2006, Pages 468-475

  Kotzailias, Nicole ^a   Andonovski, Toni ^a   Dukic, Alexander ^a   Serebruany, Victor L ^b   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Platelet function; Platelet function analyzer (PFA 100); Randomized controlled trial; Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

ACETYLSALICYLIC ACID; PADGEM PROTEIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; FLOW CYTOMETRY; HUMAN; MALE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SHEAR STRESS; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS;

ADULT; ASPIRIN; COLLAGEN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; EPINEPHRINE; FLOW CYTOMETRY; HUMANS; MALE; P-SELECTIN; PAROXETINE; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; SEROTONIN UPTAKE INHIBITORS; SMOKING;

EID: 33644979767     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006286432     Document Type: Article

References (54)

1. Carney RM, Freedland KE, Jaffe AS. Depression as a risk factor for coronary heart disease mortality. Arch Gen Psychiatry. 2001;58:229-230.
2. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898.
3. Carney RM, Rich MVV, Tevelde A, Saini J, Clark K, Jaffe AS. Major depressive disorder in coronary artery disease. Am J Cardiol. 1987;60:1273-1275.
4. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events: SHEP Cooperative Research Group (systolic hypertension in the elderly). Arch Intern Med. 1996;156:553-561.
5. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270:1819-1825.
6. Swenson JR, O'Connor CM, Barton D, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group: influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol. 2003;92:1271-1276.
7. House A. Depression after stroke. Br Med J. (Clin Res Ed) 1987;294(6564):76-78.
8. Gainotti C, Marra G. Determinants and consequences of post-stroke depression. Curr Opin Neurol. 2002;15:85-89.
9. Gupta A, Pansari K, Shetty H. Post-stroke depression. Int J Clin Pract. 2002;56:531-537.
10. Morris PL, Raphael B, Robinson RG. Clinical depression is associated with impaired recovery from stroke. Med J Aust. 1992;157:239-242.
11. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression - a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347-351.
12. Willerson JT, Eidt JF, McNatt J, et al. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. J Am Coll Cardiol. 1991;17(suppl B):101B-110B.
13. Vanhoutte PM. Serotonin, hypertension and vascular disease. Neth J Med. 1991;38:35-42.
14. Araki S, Kawahara Y, Fukuzaki H, Takai Y. Serotonin plays a major role in serum-induced phospholipase C-mediated hydrolysis of phosphoinositides and DNA synthesis in vascular smooth muscle cells. Atherosclerosis. 1990;83:29-34.
15. Biondi ML, Agostoni A, Marasini B. Serotonin levels in hypertension. J Hypertens. 1986;4(suppl):S39-S41.
16. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 1988;18:399-404.
17. Ding YA, Chou TC, Huan R. Are platelet cytosolic free calcium, serotonin concentration and blood viscosity different between hypertensive and normotensive subjects? Cardiology. 1994;85:76-81.
18. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(suppl):42-48.
19. Serebruany VL, Glassman AH, Malinin AI, et al. Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy [erratum appears in Circulation. 2003;108:3165] Circulation. 2003;108:939-944.
20. De Abajo FJ, Rodriguez LAG, Montero D. Association between the selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population-based case-control study. Br Med J. 1999;19:1106-1109.
21. Layton D, Clark DW, Pearce GL, Shakir SA. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol. 2001;57:167-176.
22. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000;68:435-442.
23. Kawano H, Tsuji H, Nishimura H, et al. Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood. 2001;97:1697-1702.
24. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail. 2003;5:517-521.
25. Pernersdorfer T, Stohlawetz P, Stummvoll G, et al. Low-dose aspirin does not lower platelet activation in vivo in healthy smokers. Br J Haematol. 1998;102:1229-1231.
26. Sparrow D, O'Connor GT, Young JB, Rosner B, Weiss ST. Relationship of urinary serotonin excretion to cigarette smoking and respiratory syndromes: the Normative Aging Study. Chest. 1992;101:976-980.
27. Wolff B, Grabe HJ, Volzke H, et al. A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. Thromb Haemost. 2005;93:180-182.
28. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost. 2000;83:316-321.
29. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152-163.
30. Borzini P, Lazzaro A, Mazzucco L. Evaluation of the hemostatic function of stored platelet concentrates using the platelet function analyzer (PFA-100). Haematologica. 1999;84:1104-1109.
31. Gianetti J, Parri MS, Sbrana S, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res. 2005 Dec 9; PMID: 16343603 [Epub ahead of print].
32. Sambola A, Heras M, Escolar G, et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets. 2004;15:439-446.
33. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets. 2002;13:493-497.
34. Jilma B, Fuchs I, Spiel A, Laggner A, Frossard M. Platelet hyperfunction and low response to aspirin predict re-events in patients with acute coronary syndromes during long-term follow-up. Circulation. 2005;112:II-690:3233.
35. Stohlawetz P, Horvath M, Pernerstorfer T, et al. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion. 1999;39:506-514.
36. Koyama H, Maeno T, Fukumoto S, et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation. 2003;108:524-529.
37. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
38. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43:453-462.
39. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392-1397.
40. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel and both after ischemic stroke: a case-crossover study. Stroke. 2003;34:849-855.
41. Gianetti J, Parri MS, Sbrana S, et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res. In press.
42. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost. 2001;86:880-886.
43. Van der Planken MG, Claeys MJ, Vertessen FJ, et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res. 2003;111:159-164.
44. Harrison P, Robinson M, Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol. 2002;24:225-232.
45. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32-26.
46. Turner-Stokes L, Hassan N. Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: treatment alternatives. Clin Rehabil. 2002;16:248-260.
47. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718-779.
48. Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage. 2002;15:26-36.
49. Golino P, Piscione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994;330:523-528.
50. Kotzailias N, Marker M, Jilma B. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2004;24:536-539.
51. Alvarez JC, Gluck N, Arnulf I, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999;66:617-624.
52. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185-2192.
53. Jilma B, Eichler HG, Vondrovec B, et al. Effects of desmopressin on circulating P-selectin. Br J Haematol [comment in: Br J Haematol. 1996;95:570-571]. 1996;93:432-436.
54. Blann AD, Devine C, Amiral J, McCollum CN. Soluble adhesion molecules, endothelial markers and atherosclerosis risk factors in abdominal aortic aneurysm: a comparison with claudicants and healthy controls. Blood Coagul Fibrinolysis. 1998;9:479-484.